LFG
TRVI icon

Larson Financial Group’s Trevi Therapeutics TRVI Stock Holding History

Larson Financial Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5K Buy
1,047
+1,038
+11,533% +$11.6K ﹤0.01% 2110
2025
Q4 		$113 Buy
9
+6
+200% +$69 ﹤0.01% 3331
2025
Q3 		$27 Buy
+3
New +$22 ﹤0.01% 3384

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Larson Financial Group's TRVI Position: Q1 2026 in Review

Larson Financial Group increased its Trevi Therapeutics (TRVI) stake by 11,533% in Q1 2026, buying an estimated $11.6K and bringing the position to 1,047 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Larson Financial Group first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Larson Financial Group held 1,047 shares of Trevi Therapeutics worth $12.5K as of Q1 2026.
  • Larson Financial Group bought 1,038 Trevi Therapeutics shares in Q1 2026, an estimated $11.6K.
  • Trevi Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2110 holding.
  • Larson Financial Group first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.